- Home
- CEV vs XGN Comparison
CEV vs XGN Comparison
Compare CEV & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CEV | XGN |
|---|---|---|
| Founded | N/A | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.6M | 71.2M |
| IPO Year | 1998 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CEV | XGN |
|---|---|---|
| Price | $10.31 | $4.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $8.86 |
| AVG Volume (30 Days) | 26.9K | ★ 401.9K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $8.12 |
| Revenue Next Year | N/A | $13.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.35 | $2.59 |
| 52 Week High | $10.78 | $12.23 |
Technical Indicators
Market Signals| Indicator | CEV | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 52.63 | 57.89 |
| Support Level | $9.94 | $2.68 |
| Resistance Level | $10.49 | $5.55 |
| Average True Range (ATR) | 0.13 | 0.42 |
| MACD | 0.02 | -0.07 |
| Stochastic Oscillator | 50.33 | 36.81 |
Price Performance
Historical ComparisonAbout CEV Eaton Vance California Municipal Income Trust Shares of Beneficial Interest
Eaton Vance CA Muni Income Trust is a non-diversified closed-end investment company. The company's investment objective is to provide current income exempt from regular federal income tax and California state personal income taxes. It invests in municipal obligations, issued by the State of California or its political subdivisions, agencies, authorities and instrumentalities and also has some exposure to corporate bonds.
About XGN Exagen Inc.
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.